Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

Ben De Pauw,* Thomas J. Walsh,* J. Peter Donnelly,* David A. Stevens, John E. Edwards, Thierry Calandra, Peter G. Pappas, Johan Maertens, Olivier Lortholary, Carol A. Kauffman, David W. Denning, Thomas F. Patterson, Georg Maschmeyer, Jacques Bille, William E. Dismukes, Raoul Herbrecht, William W. Hope, Christopher C. Kibbler, Bart Jan Kullberg, Kieren A. Marr, Patricia Muñoz, Frank C. Odds, John R. Perfect, Angela Restrepo, Markus Ruhnke, Braham H. Segal, Jack D. Sobel, Tania C. Sorrell, Claudio Viscoli, John R. Wingard, Theoklis Zaoutis, and John E. Bennett diagnoses are important causes of morbidity and mortality. Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies.

Methods. After the introduction of the original European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group definitions, advances in diagnostic technology and the recognition of areas in need of improvement led to a revision of this document. The revision process started with a meeting of participants in 2003, to decide on the process and to draft the proposal. This was followed by several rounds of consultation until a final draft was approved in 2005. This was made available for 6 months to allow public comment, and then the manuscript was prepared and approved.

Results. The revised definitions retain the original classifications of “proven,” “probable,” and “possible” invasive fungal disease, but the definition of “probable” has been expanded, whereas the scope of the category “possible” has been diminished. The category of proven invasive fungal disease can apply to any patient, regardless of whether the patient is immunocompromised, whereas the probable and possible categories are proposed for immunocompromised patients only.

Conclusions. These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.
international researchers. The definitions assigned 3 levels of probability to the diagnosis of invasive fungal infection that develops in immunocompromised patients with cancer and in hematopoietic stem cell transplant recipients—namely, “proven,” “probable,” and “possible” invasive fungal infection. The definitions established a formal framework for defining invasive fungal infection with a variable certainty of diagnosis. Proven invasive fungal infection required only that a fungus be detected by histological analysis or culture of a specimen of tissue taken from a site of disease; in the case of Cryptococcus neoformans, detection of capsular antigen in CSF or a positive result of an India ink preparation of CSF was considered sufficient to establish a diagnosis of proven cryptococcosis. By contrast, probable and possible invasive fungal infections hinged on 3 elements—namely, a host factor that identified the patients at risk, clinical signs and symptoms consistent with the disease entity, and mycological evidence that encompassed culture and microscopic analysis but also indirect tests, such as antigen detection. These EORTC/MSG Consensus Group definitions have been used in major trials of antifungal drug efficacy, in strategy trials [2–6], for the formulation of clinical practice guidelines [7], for validation of diagnostic tests [8–13], and for performance of epidemiologic studies [14].

The previously published definitions were not without their shortcomings. For instance, the original category of possible invasive fungal infection allowed too many dubious cases to be included, particularly those involving neutropenia, nonspecific pulmonary infiltrates, and persistent fever refractory to broad-spectrum antibiotics but with no evidence of invasive fungal infection [15]. These cases may represent patients at higher risk of invasive fungal infection but are quite different from the cases, also defined as possible cases, for which more specific pulmonary abnormalities, such as a halo or air-crescent sign characteristic of invasive aspergillosis, were present. Indeed, the definitions were modified to allow enrollment of similar cases into clinical trials, because they are considered to represent likely invasive fungal disease even without supporting mycological evidence [2, 16]. This pragmatic approach solved the problem of recruitment of representative cases, but it clearly highlighted the need to refine further the definitions, to distinguish dubious cases from the more likely cases when mycological evidence was not forthcoming. The growing body of evidence regarding the value of high-resolution CT of chest and abdomen [17] and of indirect diagnostic tests—such as the detection of galactomannan in body fluids other than serum and plasma, of β-D-glucan in serum, and of fungal DNA in body fluids by PCR—provided additional incentive to review the definitions [18, 19]. The original definitions were also restricted to patients with cancer and to recipients of hematopoietic stem cell transplants; however, invasive fungal infections are known to affect other populations, including recipients of solid-organ transplants and patients with primary immunodeficiencies (e.g., chronic granulomatous disorder) [20, 21]. Finally, it was considered appropriate to explore the possibility of formulating specific criteria for diseases caused by less common fungal pathogens.

REVISION PROCESS

The EORTC/MSG Consensus Group met in Chicago, Illinois, on 14 September 2003 during the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and included 13 members from the EORTC and 17 from the MSG. J. Powers also participated for the US Food and Drug Administration (FDA), and there were 5 observers from 4 pharmaceutical companies (J. Rex [Astra Zeneca], C. Sable [Merck], M. Bresnik [Gilead], and G. Triggs and A. Baruch [Pfizer]). B.d.P. and T.J.W. were confirmed as joint chairs, and J.P.D. was designated as secretary for the group. Three subcommittees were appointed to prepare proposals for mold infection, candidiasis, and endemic mycoses. The proposals were collated by the secretary, who integrated them into a general framework. They were then circulated by electronic mail to all group members. The ensuing comments again were centrally combined for a subsequent round of electronic consultation. The remaining issues that appeared difficult to solve by the electronic route were addressed in open meetings during the 15th European Congress of Clinical Microbiology and Infectious Disease in Copenhagen, Denmark, and the 45th Annual ICAAC in Washington, DC. A majority vote was decisive when a consensus among the members could not be achieved. The final draft was made available to the wider community for comment at the Doctor Fungus Web site [22] and The Aspergillus Web site [23]. Thereafter, the manuscript was prepared and was circulated among all group members for their final approval.

At the first meeting, all group members agreed to the need to refine and revise the definitions. It was also agreed unanimously that the definition set should remain easily reproducible and should offer the opportunity for a reasonable comparison of future data sets with data sets that had been collected in clinical trials that involved patients with proven and probable invasive fungal infections according to the original definitions. Finally, the group set out to reexamine the feasibility of using the definitions for treatment purposes, to devise a means of extending their applicability to other patient groups, to review the relevance of the findings obtained from studies based on the definitions for clinical practice, and to attempt to incorporate all the available laboratory tests and imaging techniques into the definitions.
REVISED DEFINITIONS

The term “invasive fungal disease” (IFD) was adopted to reflect more accurately the notion that we are dealing with a disease process caused by fungal infection. An adequate diagnostic evaluation of the infectious disease process, to exclude an alternative etiology, was deemed to be a necessary prerequisite to classify it as an IFD. The group reaffirmed that the definitions should be used only to assist in research and that the integrity of the original definitions with the classifications of proven, probable, and possible IFD would be preserved (tables 1–3). Infections caused by *Pneumocystis jiroveci* are not included. The criteria for proven and probable IFD (tables 1 and 2) were modified to reflect advances in indirect tests, whereas the category of possible IFD (table 3) was revised to include only cases that are highly likely to be caused by a fungal etiology, although mycological evidence is lacking. Hence, the definitions of probable and possible IFD were based on the same 3 elements as were the original definitions: host factors, clinical manifestations, and mycological evidence.

Host factors are not synonymous with risk factors but are characteristics by which individuals predisposed to acquire IFD can be recognized. Consequently, the presence of fever was removed as a host factor because it represents a clinical feature, not a host factor, and is nonspecific for IFD. The host factors were extended to receipt of a solid-organ transplant, hereditary immunodeficiencies, connective tissue disorders, and receipt of immunosuppressive agents—for example, corticosteroids or T cell immunosuppressants, such as calcineurin inhibitors, anti-TNF-α drugs, anti-lymphocyte antibodies, or purine analogues.

The distinction between “minor” and “major” clinical criteria was abandoned in favor of more-characteristic and objectively verifiable evidence, such as the findings on medical imaging that indicated a disease process consistent with IFD by use of a standardized glossary of definitions. For example, in the case of chest CT imaging to categorize pulmonary lesions, the vast majority of immunocompromised patients with invasive pulmonary aspergillosis have focal rather than diffuse pulmonary infiltrates and present with at least 1 macronodule, with or without a halo sign [24]. These infections can also manifest as wedge-shaped infiltrates and segmental or lobar consolidation. Although none of the imaging findings is pathognomonic for IFD, the observation that, in the appropriate patient population, the outcome of antifungal therapy did not differ between febrile patients with nodular lesions and patients with mycological evidence of an IFD supports the use of this clinical criterion [17]. A similar consideration applies to patients with lesions on CT or ultrasound that are regarded as typical for chronic disseminated candidiasis. In the original definitions, patients with such lesions were defined as having probable hepatosplenic candidiasis without any need for mycological support. In the revised definitions, such cases are classified as possible IFD, thereby retaining the consistency of the definitions and preserving the distinction between probable IFD and possible IFD. For a patient with appropriate host factors and clinical evidence of pulmonary disease, bronchoalveolar lavage fluid that yields *Aspergillus*, Zygomycetes, *Fusarium*, or *Scedosporium* species or other pathogenic molds would constitute mycological support and would allow the case to be classified as probable pulmonary IFD.

As with the original definitions, indirect tests were considered for inclusion only if they were validated and standardized. Furthermore, because commercial tests for diagnostic use had to provide criteria for interpretation to gain approval, it was decided to rely entirely on the thresholds recommended by the manufacturer. On the basis of recent studies, the Platelia *Aspergillus* galactomannan EIA could be applied to CSF and bronchoalveolar lavage fluid, as well as plasma and serum. The β-D-glucan assay also was included as a marker for probable IFD, because this test detects other species of fungi besides *Aspergillus*, and a commercial test for it (Fungitell assay; Associates of Cape Cod) has been approved by the FDA. By contrast, molecular methods of detecting fungi in clinical specimens, such as PCR, were not included in the definitions because there is as yet no standard, and none of the techniques has been clinically validated.

THE CATEGORIES

**Proven IFD.** There was general agreement that the category of proven IFD should be retained, requiring proof of IFD by demonstration of fungal elements in diseased tissue for most conditions (table 1). Revisions were made to this category to reflect advances in indirect assays that are highly specific for the infection being detected. By its very nature, this category is likely to be valid irrespective of host factors or clinical features. Individual IFD entities—for example, proven aspergillosis—require culture and identification. Failing this, the disease is designated as proven mold IFD (table 1). The histological appearance of the endemic dimorphic fungi, *Histoplasma capsulatum*, as small intracellular budding yeasts; *Coccidioides* species as spherules; *Paracoccidioides brasiliensis* as large yeasts with multiple daughter yeasts in a “pilot-wheel configuration”; and *Blastomyces dermatitidis* as thick-walled, broad-based budding yeasts is sufficiently distinctive to permit a definitive diagnosis (table 3). *H. capsulatum* variety *capsulatum* resembles *Candida glabrata* or *Leishmania* species in tissue but can be distinguished from them by characteristic histological features of granulomatous inflammation in histoplasmosis in some patient groups and by staining with silver, which shows staining for the fungi but not for *Leishmania* species.

The category of proven IFD was modified to reflect advances...
Table 1. Criteria for proven invasive fungal disease except for endemic mycoses.

<table>
<thead>
<tr>
<th>Analysis and specimen</th>
<th>Molds&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Yeasts&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microscopic analysis: sterile material</td>
<td>Histopathologic, cytopathologic, or direct microscopic examination&lt;sup&gt;b&lt;/sup&gt; of a specimen obtained by needle aspiration or biopsy in which hyphae or melanized yeast-like forms are seen accompanied by evidence of associated tissue damage</td>
<td>Histopathologic, cytopathologic, or direct microscopic examination&lt;sup&gt;b&lt;/sup&gt; of a specimen obtained by needle aspiration or biopsy from a normally sterile site (other than mucous membranes) showing yeast cells—for example, Cryptococcus species indicated by encapsulated budding yeasts or Candida species showing pseudohyphae or true hyphae&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Culture</td>
<td>Recovery of a mold or “black yeast” by culture of a specimen obtained by a sterile procedure from a normally sterile and clinically or radiologically abnormal site consistent with an infectious disease process, excluding bronchoalveolar lavage fluid, a cranial sinus cavity specimen, and urine</td>
<td>Recovery of a yeast by culture of a sample obtained by a sterile procedure (including a freshly placed [&lt;24 h ago] drain) from a normally sterile site showing a clinical or radiological abnormality consistent with an infectious disease process</td>
</tr>
<tr>
<td>Blood</td>
<td>Blood culture that yields a mold&lt;sup&gt;d&lt;/sup&gt; (e.g., Fusarium species) in the context of a compatible infectious disease process</td>
<td>Blood culture that yields yeast (e.g., Cryptococcus or Candida species) or yeast-like fungi (e.g., Trichosporon species)</td>
</tr>
<tr>
<td>Serological analysis: CSF</td>
<td>Not applicable</td>
<td>Cryptococcal antigen in CSF indicates disseminated cryptococcosis</td>
</tr>
</tbody>
</table>

<sup>a</sup> If culture is available, append the identification at the genus or species level from the culture results.

<sup>b</sup> Tissue and cells submitted for histopathologic or cytopathologic studies should be stained by Grocott-Gomori methenamine silver stain or by periodic acid Schiff stain, to facilitate inspection of fungal structures. Whenever possible, wet mounts of specimens from foci related to invasive fungal disease should be stained with a fluorescent dye (e.g., calcofluor or blankophor).

<sup>c</sup> Candida, Trichosporon, and yeast-like Geotrichum species and Blastoschizomyces capitatus may also form pseudohyphae or true hyphae.

<sup>d</sup> Recovery of Aspergillus species from blood cultures invariably represents contamination.
### Table 2. Criteria for probable invasive fungal disease except for endemic mycoses.

<table>
<thead>
<tr>
<th>Host factors&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Clinical criteriab</th>
<th>Mycological criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recent history of neutropenia (&lt;0.5 × 10⁹ neutrophils/L [&lt;500 neutrophils/mm³] for &gt;10 days) temporally related to the onset of fungal disease</td>
<td>Lower respiratory tract fungal disease&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Direct test (cytology, direct microscopy, or culture)</td>
</tr>
<tr>
<td>Receipt of an allogeneic stem cell transplant</td>
<td>The presence of 1 of the following 3 signs on CT:</td>
<td>Mold in sputum, bronchoalveolar lavage fluid, bronchial brush, or sinus aspirate samples, indicated by 1 of the following:</td>
</tr>
<tr>
<td>Prolonged use of corticosteroids (excluding among patients with allergic bronchopulmonary aspergillosis) at a mean minimum dose of 0.3 mg/kg/day of prednisone equivalent for &gt;3 weeks</td>
<td>Dense, well-circumscribed lesion(s) with or without a halo sign</td>
<td>Presence of fungal elements indicating a mold</td>
</tr>
<tr>
<td>Treatment with other recognized T cell immunosuppressants, such as cyclosporine, TNF-α blockers, specific monoclonal antibodies (such as alemtuzumab), or nucleoside analogues during the past 90 days</td>
<td>Air-crescent sign</td>
<td>Recovery by culture of a mold (e.g., <em>Aspergillus, Fusarium, Zygomycetes, or Scedosporium</em> species)</td>
</tr>
<tr>
<td>Inherited severe immunodeficiency (such as chronic granulomatous disease or severe combined immunodeficiency)</td>
<td>Cavity</td>
<td>Indirect tests (detection of antigen or cell-wall constituents)&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical criteriab</th>
<th>Disseminated candidiasisd</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tracheobronchitis</td>
<td>At least 1 of the following 2 entities after an episode of candidemia within the previous 2 weeks:</td>
</tr>
<tr>
<td>Tracheobronchial ulceration, nodule, pseudomembrane, plaque, or eschar seen on bronchoscopic analysis</td>
<td>Small, target-like abscesses (bull’s-eye lesions) in liver or spleen</td>
</tr>
<tr>
<td>Sinonasal infection</td>
<td>Progressive retinal exudates on ophthalmologic examination</td>
</tr>
<tr>
<td>Imaging showing sinusitis plus at least 1 of the following 3 signs:</td>
<td>Invasive fungal disease other than cryptococcosis and zygomycoses</td>
</tr>
<tr>
<td>Acute localized pain (including pain radiating to the eye)</td>
<td>β-1,3-glucan detected in serum</td>
</tr>
<tr>
<td>Nasal ulcer with black eschar</td>
<td></td>
</tr>
<tr>
<td>Extension from the paranasal sinus across bony barriers, including into the orbit</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CNS infection</th>
<th>Mycological criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 of the following 2 signs:</td>
<td>Direct test (cytology, direct microscopy, or culture)</td>
</tr>
<tr>
<td>Focal lesions on imaging</td>
<td>Mold in sputum, bronchoalveolar lavage fluid, bronchial brush, or sinus aspirate samples, indicated by 1 of the following:</td>
</tr>
<tr>
<td>Meningeal enhancement on MRI or CT</td>
<td>Presence of fungal elements indicating a mold</td>
</tr>
</tbody>
</table>

**NOTE.** Probable IFD requires the presence of a host factor, a clinical criterion, and a mycological criterion. Cases that meet the criteria for a host factor and a clinical criterion but for which mycological criteria are absent are considered possible IFD.

<sup>a</sup> Host factors are not synonymous with risk factors and are characteristics by which individuals predisposed to invasive fungal diseases can be recognized. They are intended primarily to apply to patients given treatment for malignant disease and to recipients of allogeneic hematopoietic stem cell and solid-organ transplants. These host factors are also applicable to patients who receive corticosteroids and other T cell suppressants as well as to patients with primary immunodeficiencies.

<sup>b</sup> Must be consistent with the mycological findings, if any, and must be temporally related to current episode.

<sup>c</sup> Every reasonable attempt should be made to exclude an alternative etiology.

<sup>d</sup> The presence of signs and symptoms consistent with sepsis syndrome indicates acute disseminated disease, whereas their absence denotes chronic disseminated disease.

<sup>e</sup> These tests are primarily applicable to aspergillosis and candidiasis and are not useful in diagnosing infections due to *Cryptococcus* species or *Zygomycetes* (e.g., *Rhizopus, Mucor, or Absidia* species). Detection of nucleic acid is not included, because there are as yet no validated or standardized methods.
in our understanding of Coccidioides serological characteristics. Consequently, the presence of coccidoidal antibody in CSF was considered to be sufficient to fulfill the criteria for proven coccidioidomycosis. Similarly, the presence of capsular antigen in CSF was considered to be sufficiently distinctive to establish a diagnosis of disseminated cryptococcosis [25]. Urinary Histoplasma antigen supports a diagnosis of probable endemic mycosis, in conjunction with appropriate host and clinical criteria (table 3), but cannot be considered sufficient evidence of proven histoplasmomiasis, because Histoplasma antigen is also found in urine and serum of patients with coccidioidomycosis and blastomycosis [26].

**Probable IFD.** Cases of probable IFD require that a host factor, clinical features, and mycological evidence be present, as outlined in tables 2 and 3.

**Possible IFD.** The category of possible IFD was retained but was defined more strictly to include only those cases with the appropriate host factors and with sufficient clinical evidence consistent with IFD but for which there was no mycological support (table 2). However, this category was not considered appropriate for endemic mycosis, because host factors and clinical features are not sufficiently specific and because such cases would be of value too limited to include in clinical trials, epidemiological studies, or evaluations of diagnostic tests.

**COMMENTS**

**Implications of the revised category of possible IFD.** After enrollment into an interventional or diagnostic study, every effort should be made to upgrade the certainty of diagnosis for patients with possible IFD to the category of proven or probable IFD. These definitions may be applied at different times during the period of risk. For example, although a case might not meet the definition of possible, probable, or proven IFD at the beginning of a period of high risk, during which prophylaxis is given, the case may continue to evolve, such that the criteria may be met later.

The overrepresentation of dubious cases that resulted from the application of the original definitions made it imperative to redress the balance and to capture more patients with a higher probability of IFD while excluding patients who are unlikely to have invasive mycosis. Some members even argued that the category of possible IFD, as defined in the original set of definitions, should be abolished altogether. However, such a decision would reduce dramatically the number of candidates eligible for clinical studies of fungal pneumonia, making randomized trials nearly impossible to conduct. The corollary of retaining a better-defined category of possible IFD, to reduce the number of doubtful cases, was that greater emphasis was placed on mycological evidence for the categories of proven and probable IFD. This allows the category of possible IFD to be reserved for clinical manifestations fully consistent with fungal etiology but for which there is no mycological evidence available, although a reasonable attempt has been made to exclude an alternative etiology.

**Non–culture-based diagnostic tests.** There was much discussion about indirect mycological tests, especially assays for detection of antigen and β-d-glucan. Since the first definitions were published [1], the FDA has approved the Aspergillus galactomannan EIA and, more recently, the assay for β-d-glucan, on the grounds that they were standardized, were validated, are available, and are fit to convey useful information [8, 19, 27]. However, controversy arose about the interpretation of the index for the galactomannan assay, which was originally set at 1.5 and was applied in Europe but which was lowered to 0.5
after review by the FDA. This cutoff value has been shown recently to improve the overall performance of the test for adult hematologic patients [28]. Because the issue remains contentious, the decision was made to place the onus on the manufacturers of commercial tests and to adopt whatever threshold values they recommend.

We had hoped that nucleic acid–detection tests, such as PCR, would have improved enough to incorporate the results of these tests into the definitions. However, standardization and validation have not yet been attained for these platforms.

**Limitations of the revised definitions.** The revised definitions apply to immunocompromised patients but not necessarily to critically ill patients in the intensive care unit who, nonetheless, may develop possible or probable IFD [29]. The group recognized this as an omission but was unable to find a sufficient basis for identifying the appropriate host factors, even though there may be mycological evidence, such as recovery of *Aspergillus* species from bronchial secretions or a positive β-d-glucan test result. The group, therefore, concluded that the body of evidence supporting a diagnosis other than proven IFD is not sufficiently mature at present.

The definitions are not a substitute for complete clinico-pathologic descriptions and classifications of IFD, as have been published recently for aspergillosis [21]. The failure to meet the criteria for IFD does not mean that there is no IFD, only that there is insufficient evidence to support the diagnosis. This is the most compelling reason for not employing these definitions in daily clinical practice.

We anticipate that the field of diagnosis will continue to evolve, so that there will come a time when the definitions may be formally evaluated for their sensitivity and specificity. Until then, additional revisions of the present set of definitions are likely, but they should be contemplated carefully. The words and phrases chosen here were selected on the basis of extensive debate and discussion. Seemingly, slight changes may have unexpectedly profound consequences in the design, implementation, and interpretation of clinical trials.

These revised definitions of IFD categories are intended to advance clinical and epidemiological research and, as such, may serve as a useful model for defining other infections in high-risk patients. The definitions are not meant to be used to guide clinical practice but must be applied consistently if they are to continue to achieve their primary goal of fostering communication, furthering our understanding of the epidemiology and evolution of IFD, and facilitating our ability to test the efficacy of therapeutic regimens and strategies.

**AUTHOR AFFILIATIONS**

Departments of Blood Transfusion Service and Transplant Immunology (B.d.P.), Hematology (J.P.D.), and Internal Medicine (B.J.K.), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute (T.J.W.), and Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases (I.E.B.), National Institutes of Health, Bethesda, Maryland; Santa Clara Valley Medical Center, San Jose (D.A.S.), Stanford University, Palo Alto (D.A.S.), and Los Angeles Biomedical Research Institute at Harbor–University of California Los Angeles Medical Center, Torrance (J.E.E.), California; Division of Infectious Diseases, Department of Medicine, University of Alabama, Birmingham (P.G.P., W.E.D.); Infectious Diseases Division, Department of Internal Medicine, Ann Arbor Veterans Affairs Healthcare System, University of Michigan Medical School, Ann Arbor (C.A.K.); The University of Texas Health Science Center at San Antonio, Department of Medicine and Infectious Diseases, San Antonio (T.F.P.); Division of Infectious Diseases, Oregon Health and Science University, Portland (K.A.M.); Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina (J.R.P.); Department of Medicine, State University of New York at Buffalo, Roswell Park Cancer Institute, Buffalo (B.H.S.); Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan (J.D.S.); Division of Hematology and Oncology, University of Florida Shands Cancer Center, Gainesville (J.R.W.); Pediatric Infectious Diseases, The Children’s Hospital of Philadelphia, The Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia (T.Z.); Infectious Diseases Service, Department of Internal Medicine (T.C.), and Clinical Microbiology Laboratory (J.B.), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium (J.M.); Service des Maladies Infectieuses et Tropicales, Hopital Necker, Paris (O.L.), and Hematology and Oncology Department, University Hospital of Strasbourg, Strasbourg (R.H.), France; Education and Research Centre, Wythenshawe Hospital (D.W.D.), and University of Manchester (W.W.H.), Manchester, Department of Medical Microbiology, Royal Free Hospital, London (C.C.K.), and Aberdeen Fungal Group, Institute of Medical Sciences, University of Aberdeen, Aberdeen (F.C.O.), United Kingdom; Medizinische Klinik, Abteilung Hamatologie und Onkologie, Klinikum Ernst von Bergmann, Potsdam (G.M.), and Charité Universitätsmedizin, Campus Charité Mitte, Medizinische Klinik und Poliklinik II, Berlin (M.R.), Germany; Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Maranon, University of Madrid, Madrid, Spain (P.M.); Corporacion para Investigaciones Biologicas, Carrera, Medellin, Colombia (A.R.); Centre for Infectious Diseases and Microbiology and National Health and Medical Research Council’s Centre for Clinical Research Excellence in Infections, Bioethics and Haematological...
Malignancies, Westmead Millennium Institute, University of Sydney, Sydney, Australia (T.C.S.); and Infectious Diseases, University of Genova and San Martino University Hospital, Genoa, Italy (C.V.).

Acknowledgments

We thank Chris Bentzen, Malcolm Finkelman, Richard Summerbell, Mai-ken Cavling Arendrup, Brigitte Crepin, and John H. Rex for their constructive comments.

Financial support. Unconditional grants were provided to the Infectious Disease Group of the European Organisation for Research and Treatment of Cancer by Merck Sharp & Dohme, Pfizer and Gilead Sciences to meet the costs of the meetings and administration.

Potential conflicts of interest. B.d.P. has been an advisor/consultant for Basilea Pharmaceutica and Ipsat Therapies and has been on the speakers’ bureau for Gilead Sciences, Merck & Co (Merck), and Pfizer. J.P.D. has received grant support from AM-Pharma, Basilea Pharmaceutica, and Schering-Plough; has been an advisor/consultant for Gilead Sciences, Ipsat Therapies, and Pfizer; has been on the speakers’ bureau for Gilead Sciences, Janssen Pharmaceuticals, Pfizer, Schering-Plough, and Xian-Janssen; and has received travel grants from Merck Sharp & Dohme and UCB Pharma. J.E.E. has been an advisor/consultant for Cerexa, Merck, and Pfizer; has received grant support from Gilead Sciences, the National Institutes of Health, Merck, and Pfizer; and holds shares of NovaDigm Therapeutics. T.C. has received grant support from Bio-Rad Laboratories, Essex Pharma, Merck, Roche Diagnostics, and Wako; has been an advisor/consultant for Essex Pharma, Merck Sharp & Dohme, Novartis, and Pfizer; and has been on the speakers’ bureau for Merck Sharp & Dohme and Pfizer. P.G.P. has received grant support from Astellas Pharma, Merck, Pfizer, and Schering-Plough; has been an advisor/consultant for Astellas Pharma, Merck, Pfizer, and Schering-Plough; and has been on the speakers’ bureau for Astellas Pharma, Merck, Pfizer, and Schering-Plough; has been an advisor/consultant for Astellas Pharma, Basilea Pharmaceutica, Genzyme, Merck, Pfizer, and Schering-Plough; and has been a speaker for UCB Pharma. B.d.P. has been an advisor/consultant for Astellas Pharma and Enzon, Merck, Pfizer, and Schering-Plough. M.R. has received grant support from Merck Sharp & Dohme and Pfizer; has been an advisor/consultant for Astellas Pharmaceu-tica, Essex Pharma, Gilead Sciences, Merck Sharp & Dohme, Novartis, and Pfizer; and has been on the speakers’ bureau for Essex Pharma, Gilead Sciences, Merck Sharp & Dohme, Novartis, and Pfizer. B.H.S. has received grant support from Pfizer; has been an advisor/consultant for Berlex Laboratories, Pfizer, and Schering-Plough; and has been on the speakers’ bureau for Merck and Pfizer. I.D.S. has received grant support from Merck, the National Institutes of Health, and Pfizer; has been an advisor/consultant for Merck and Pfizer; and has been on the speakers’ bureau for Merck, Pfizer, and Schering-Plough. T.C.S. has received grant support from Gilead Sciences, Merck Sharp & Dohme, and Pfizer and has been on the speakers’ bureau for Astellas Pharma, Gilead Sciences, Merck Sharp & Dohme, Pfizer, and Schering-Plough. B.H.S. has received grant support from Pfizer; has been an advisor/consultant for Astellas Pharma, Basilea Pharmaceutica, Enzon, Merck, Pfizer, and Schering-Plough; has been a speaker for Esponam, Merck Sharp & Dohme, Pfizer, Schering-Plough, and Syngenta; has been on the speakers’ bureau for Astellas Pharma, Merck Sharp & Dohme, Pfizer, and Schering-Plough; and has been on the speakers’ bureau for Pfizer and Schering-Plough. K.A.M. has been an advisor/consultant for Basilea Pharmaceutica, Enzon, Merck, Pfizer, and Schering-Plough. F.C.O. has received grant support from Merck and Sharp & Dohme; has been an advisor/consultant for Astellas Pharma, Italfarmaco, Merck Sharp & Dohme, Pfizer, Schering-Plough, and Syngenta; has been on the speakers’ bureau for Astellas Pharma, Merck Sharp & Dohme, Pfizer, Schering-Plough; and has been on the speakers’ bureau for Pfizer and Schering-Plough. B.I.J.K. has been an advisor/consultant for Basilea Pharmaceutica, Cephalon, Genzyme, Merck, Pfizer, and Schering-Plough; and has been on the speakers’ bureau for Pfizer and Schering-Plough. R.W.H. has received grant support from Astellas Pharma, Gilead Sciences, Merck, Pfizer, and Schering-Plough; and has been on the speakers’ bureau for Gilead Sciences, Pfizer, and Schering-Plough. W.W.H. has received grant support from Astellas Pharma, Gilead Sciences, and Schering-Plough and has been an advisor/consultant for Pfizer. C.C.K. has received grant support from Gilead Sciences, Merck, and Pfizer and has been an advisor/consultant for Astellas Pharma, Gilead Sciences, ICN (now Valeant), Janssen, Merck, Pfizer, and Schering-Plough. B.I.K. has been an advisor/consultant for Basilea Pharmaceutica, F2G, Novartis, Pfizer, and Schering-Plough; and has been on the speakers’ bureau for Pfizer and Schering-Plough. C.A.K. has received grant support from Astellas Pharma, Enzon, Merck, Pfizer, and Schering-Plough; and has been on the speakers’ bureau for Astellas Pharma, Enzon, Merck, Pfizer, and Schering-Plough; and has been on the speakers’ bureau for Pfizer and Schering-Plough. E.J.J.K. has received grant support from Pfizer, Enzon, and Schering-Plough; and has been on the speakers’ bureau for Pfizer and Schering-Plough. A.R. has received grant support from Pfizer; has been an advisor/consultant for Basilea Pharmaceutica, Merck, Nektar Therapeutics, and Pfizer; and has been on the speakers’ bureau for Pfizer and Schering-Plough. T.Z. has received grant support from Pfizer for Merck and Pfizer; has been on the speakers’ bureau for Merck, Pfizer, and Schering-Plough. T.C.S. has received grant support from Gilead Sciences, Merck Sharp & Dohme, and Pfizer and has been on the speakers’ bureau for Astellas Pharma, Gilead Sciences, Merck Sharp & Dohme, Pfizer, and Schering-Plough; and has been an advisor/consultant for Astellas Pharma, Enzon, Merck, Pfizer, and Schering-Plough; and has been on the speakers’ bureau for Pfizer and Schering-Plough; and has been on the speakers’ bureau for Pfizer and Schering-Plough. M.R. has received grant support from Merck Sharp & Dohme and Pfizer; has been an advisor/consultant for Astellas Pharmaceutica, Essex Pharma, Gilead Sciences, Merck Sharp & Dohme, Novartis, and Pfizer; and has been on the speakers’ bureau for Essex Pharma, Gilead Sciences, Merck Sharp & Dohme, Novartis, and Pfizer. B.H.S. has received grant support from Pfizer; has been an advisor/consultant for Pfizer. C.C.K. has received grant support from Astellas Pharma, Basilea Pharmaceutica, Enzon, Merck, Pfizer, and Schering-Plough; has been an advisor/consultant for Astellas Pharma, Basilea Pharmaceutica, F2G, Novartis, Pfizer, and Schering-Plough; and has been on the speakers’ bureau for Pfizer and Schering-Plough. K.A.M. has been an advisor/consultant for Basilea Pharmaceutica, Enzon, Merck, Pfizer, and Schering-Plough. F.C.O. has received grant support from Merck and Sharp & Dohme; has been an advisor/consultant for Astellas Pharma, Italfarmaco, Merck Sharp & Dohme, Pfizer, Schering-Plough, and Syngenta; has been on the speakers’ bureau for Astellas Pharma, Merck Sharp & Dohme, Pfizer, Schering-Plough; and has been on the speakers’ bureau for Pfizer and Schering-Plough. K.A.M. has been an advisor/consultant for Basilea Pharmaceutica, Enzon, Merck, Pfizer, and Schering-Plough. F.C.O. has received grant support from Merck and Sharp & Dohme; has been an advisor/consultant for Astellas Pharma, Italfarmaco, Merck Sharp & Dohme, Pfizer, Schering-Plough, and Syngenta; has been on the speakers’ bureau for Astellas Pharma, Merck Sharp & Dohme, Pfizer, Schering-Plough; and has been on the speakers’ bureau for Pfizer and Schering-Plough. K.A.M. has been an advisor/consultant for Basilea Pharmaceutica, Enzon, Merck, Pfizer, and Schering-Plough.

References

8. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentzen C, Walsh...